ArticleEuropean urology open science2026
PRECISE Assessment of Sequential Biparametric MRI and Clinically Significant Prostate Cancer in Biopsy-naive Men: A Retrospective Cohort Study.
Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In real-world practice, some biopsy-naive men with suspected prostate cancer (PCa) defer immediate biopsy and undergo magnetic resonance imaging (MRI) follow-up, yet standardized criteria to interpret MRI changes are lacking. Objective: To evaluate the association of the Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) assessment of sequential biparametric MRI with clinically significant PCa (csPCa) at subsequent biopsy. Design setting and participants: This retrospective single-center study included 174 biopsy-naive men who underwent at least two prebiopsy MRI examinations separated by ≥12 mo between 2019 and 2025. Two blinded radiologists assigned the Prostate Imaging Reporting and Data System (PI-RADS) categories and scored interval change using PRECISE version 2. All patients underwent prostate biopsy. Outcome measurements and statistical analysis: The primary outcome was csPCa at subsequent biopsy, defined as International Society of Urological Pathology grade group ≥2. Multivariable Firth penalized logistic regression assessed factors associated with csPCa. Results and limitations: Biopsy showed no PCa in 81 of the 174 (47%) men, clinically insignificant PCa in 20 of the 174 (12%) men, and csPCa in 73 of the 174 (42%) men. The csPCa rates increased with PRECISE: 6.1% (PRECISE 2/3-NonV), 26% (3-V), and 81% (4-5). After adjustment, the natural log of repeat prostate-specific antigen density (PSAD; odds ratio [OR] 2.14, 95% confidence interval [CI] = 1.10-4.44) and PRECISE 4-5 versus 2/3-NonV (OR 15.21, 95% CI = 2.97-104.44) remained associated with csPCa. Exploratory analysis showed that integrating baseline PI-RADS assessment with longitudinal MRI changes was associated with different observed rates of csPCa detection. Limitations include retrospective single-center design and sample size. Conclusions: Sequential PRECISE assessment and repeat PSAD were associated with csPCa; prospective validation is required.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.